Table 1.
Clinical features of the patients with COVID-19
| Characteristics | Patients (n=788) |
|---|---|
| Age | |
| Median (range) | 59.5 yr (9-100 yr) |
| Distribution (n, %) | |
| ≤17 yr | 5 (0.6) |
| 18-44 yr | 149 (18.9) |
| 45-64 yr | 338 (42.9) |
| 65-74 yr | 211 (26.8) |
| ≥75 yr | 85 (10.8) |
| Sex (n, %) | |
| Male | 311 (39.5) |
| Female | 477 (60.5) |
| Contact information (n, %) | |
| Unidentified source of infection | 673 (85.4) |
| Contact with suspected case | 12 (1.5) |
| Contact with confirmed case | 103 (13.1) |
| Signs and symptoms (n, %) | |
| Fever | 431 (54.7) |
| Cough | 404 (51.3) |
| Fatigue | 232 (29.4) |
| Expectaration | 49 (6.2) |
| Asymptomatic | 44 (5.6) |
| Sore throat | 13 (1.6) |
| Shortness of breath | 38 (4.8) |
| Myalgia | 11 (1.4) |
| Chest distress or pectoralgia | 84 (10.7) |
| Headache | 9 (1.1) |
| Dyspnea | 7 (0.9) |
| Nausea and vomiting | 3 (0.4) |
| Diarrhea | 5 (0.6) |
| Rhinorrhea | 3 (0.4) |
| Tachycardia | 3 (0.4) |
| Coexisting disorder (n, %) | |
| Hypertension | 201 (25.4) |
| Diabetes | 86 (10.9) |
| Coronary heart disease | 39 (4.9) |
| Cancer | 20 (2.5) |
| Cerebrovascular disease | 17 (2.2) |
| Chronic bronchitis | 11 (1.4) |
| Hepatitis B infection | 8 (1.0) |
| Asthma | 6 (0.8) |
| Chronic obstructive pulmonary disease | 4 (0.5) |
| Congestive heart failure | 3 (0.4) |
| Chronic renal disease | 3 (0.4) |
| Cirrhosis | 2 (0.3) |
| Clinical classification (n, %) | |
| Mild | 35 (4.4) |
| Moderate | 656 (83.2) |
| Severe | 84 (10.7) |
| Critical | 13 (1.6) |
| Highest axilla-temperature during hospitalization (n, %) (normal range <37.3°C) | |
| Normal | 575 (73.0) |
| Low-grade fever | 187 (23.7) |
| Moderate fever | 18 (2.3) |
| High-grade fever | 2 (0.3) |
| Leucocytes (×109/L; normal range 3.5-9.5) (n, %) | |
| Decrease | 27 (3.4) |
| Normal | 716 (90.9) |
| Increase | 25 (3.2) |
| Neutrophils (×109/L; normal range 1.8-6.3) (n, %) | |
| Decrease | 22 (2.8) |
| Normal | 709 (90.0) |
| Increase | 37 (4.7) |
| Lymphocytes (×109/L; normal range 1.1-3.2) (n, %) | |
| Decrease | 119 (15.1) |
| Normal | 640 (81.2) |
| Increase | 9 (1.1) |
| Monocyte (×109/L; normal range 0.1-0.6) (n, %) | |
| No increase | 716 (90.9) |
| Increase | 52 (6.6) |
| Platelets (×109/L; normal range 125.0-350.0) (n, %) | |
| Decrease | 32 (4.1) |
| Normal | 705 (89.5) |
| Increase | 31 (3.9) |
| Alanine aminotransferase (U/L; normal range 0-55) (n, %) | |
| No increase | 662 (84.0) |
| Increase | 72 (9.1) |
| Aspartate aminotransferase (U/L; normal range 5-34) (n, %) | |
| No increase | 677 (85.9) |
| Increase | 57 (7.2) |
| Erythrocyte sedimentation rate (mm/H; normal range 0-15) (n, %) | |
| No increase | 95 (12.1) |
| Increase | 182 (23.1) |
| Interleukin-6 (pg/mL; normal range 0-10) (n, %) | |
| No increase | 323 (41.0) |
| Increase | 25 (3.2) |
| C-reactive protein (mg/mL; normal range 0-10) (n, %) | |
| No increase | 669 (84.9) |
| Increase | 73 (9.3) |
| Procalcitonin (ng/mL; normal range 0.0-0.05) (n, %) | |
| No increase | 371 (47.1) |
| Increase | 121 (15.4) |
| D-dimer (µg/L; normal range 0.0-1.5) Increased (n, %) | |
| No increase | 451 (57.2) |
| Increase | 43 (5.5) |
| Abnormalities on chest CT-(n, %) | |
| Ground glass shadow | 731 (92.8) |
| Reticulated nodule shadow | 413 (52.4) |
| Pulmonary Fibrosis | 118 (15.0) |
| Consolidation | 49 (6.2) |
| Adjacent pleura thickening | 16 (2.0) |
| Pleural effusion | 6 (0.8) |
| Thickening around the bronchus | 9 (1.1) |
| Normal | 35 (4.4) |
| Lesion area (n, %) | |
| Normal | 35 (4.4) |
| A few lesions | 346 (43.9) |
| Some lesions | 188 (23.9) |
| Many lesions | 151 (19.2) |
| Diffuse lesions | 61 (7.7) |
Note: yr: year; COVID-19: novel coronavirus pneumonia.